Format

Send to

Choose Destination
See comment in PubMed Commons below
JAMA Surg. 2016 Feb;151(2):147-53. doi: 10.1001/jamasurg.2015.3219.

Systemic Inflammatory Disease and Its Association With Type II Endoleak and Late Interventions After Endovascular Aneurysm Repair.

Author information

1
Department of Surgery, VA Connecticut Healthcare System, West Haven2Department of Surgery, Yale University School of Medicine, New Haven, Connecticut.
2
Department of Surgery, VA Connecticut Healthcare System, West Haven.
3
Department of Medicine, VA Connecticut Healthcare System, West Haven4Department of Medicine, Yale University School of Medicine, New Haven, Connecticut.
4
Department of Radiology, VA Connecticut Healthcare System, West Haven6Department of Radiology, Yale University School of Medicine, New Haven, Connecticut.

Abstract

IMPORTANCE:

Abdominal aortic aneurysms are associated with chronic inflammation within the aortic wall, and previous studies have suggested that chronic inflammation may be a consequence of a dysregulated and persistent autoimmune response. Persistent aortic remodeling after aneurysm repair could place the patient at risk for endoleak or sac rupture.

OBJECTIVE:

To determine whether patients with systemic inflammatory disease and large aneurysms have persistent aortic remodeling after endovascular aneurysm repair (EVAR).

DESIGN, SETTING, AND PARTICIPANTS:

The records of all patients who underwent EVAR between July 2002 and June 2011 at the Veterans Affairs Connecticut Healthcare System were included in this retrospective review. Patients were considered to have a systemic inflammatory disease when confirmed by a referring specialist. Post-EVAR surveillance was performed by yearly imaging.

INTERVENTION:

Endovascular aneurysm repair.

MAIN OUTCOMES AND MEASURES:

Significant endoleak, defined as endoleak and sac diameter increase of 0.5 cm or greater.

RESULTS:

A total of 51 of 79 patients (65%) had a systemic inflammatory disease. These patients had similar comorbid conditions compared with patients without inflammation but significantly greater numbers of major postoperative complications after EVAR (23.5% vs 3.6%; P = .02) and overall postoperative complications after EVAR (27.5% vs 7.1%; P = .03). Patients with a history of systemic inflammatory disease developed more endoleaks (45.1% vs 17.9%; P = .02) and late sac expansion (51.0% vs 21.4%; P = .01) and required more interventions (21.6% vs 3.6%; P = .03) during long-term follow-up. Systemic inflammatory disease was significantly associated with significant endoleak (odds ratio, 5.18; 95% CI, 1.56-17.16; P = .007).

CONCLUSIONS AND RELEVANCE:

Patients with systemic inflammatory disease are at high risk for postoperative complications, type II endoleak, sac expansion, and additional interventions after EVAR. Additional strategies for improving the efficacy of EVAR in these patients may be warranted.

PMID:
26501863
DOI:
10.1001/jamasurg.2015.3219
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center